MAXION
Live / Allowed — Published for opposition (as of 17 Feb 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 07 Oct 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 79412149
- Mark type
- Stylized text
- Filed
- 07 Oct 2024
- Published for opposition
- 17 Feb 2026
- Attorney of record
- Ben Natter
Goods and services
- Class 001 — Chemicals: Biochemicals, namely, polypeptides and engineered antibodies for scientific, laboratory or research purposes; polypeptides and engineered antibodies for use in the manufacture of pharmaceuticals and drugs; ion channel modulating and G-protein-coupled receptor modulating engineered antibodies for scientific, laboratory or research purposes; ion channel modulating and G-protein-coupled receptor modulating engineered antibodies for use in the manufacture of pharmaceuticals and drugs; engineered antibodies derived from mini-protein toxins for scientific, laboratory or research purposes; engineered antibodies derived from mini-protein toxins for use in the manufacture of pharmaceuticals and drugs
- Class 005 — Pharmaceuticals: Pharmaceuticals and pharmaceutical preparations for the treatment of diseases and conditions associated with dysregulation of ion channel and G-protein-coupled receptor activity, in particular, preparations for the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; drugs, namely, pharmaceutical preparations for the treatment of diseases and conditions associated with dysregulation of ion channel and G-protein-coupled receptor activity, in particular, those for use in the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; antibodies for medical use; pharmaceuticals and drugs in the nature of pharmaceutical preparations incorporating antibodies, ion channel modulating antibodies, and G-protein-coupled receptor modulating antibodies or antibodies derived from mini-protein toxins for the treatment of diseases and conditions associated with dysregulation of ion channel and G-protein-coupled receptor activity, in particular, those for the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; human vaccine preparations
- Class 042 — Scientific and technological services: Scientific and technological services and research and design relating thereto, namely scientific research, analysis and testing in the fields of pharmaceuticals, biochemicals, polypeptides, antibodies, ion channel modulating antibodies, and G-protein-coupled receptor modulating antibodies and antibodies derived from mini-protein toxins; drug discovery and drug development services; conducting or providing research and development services for others in the field of antibodies; medical and scientific laboratory services relating to the production of antibodies, ion channel modulating and G-protein-coupled receptor modulating antibodies or antibodies derived from mini-protein toxins; antibody engineering; scientific research services relating to the discovery, preclinical and clinical development of therapeutic products; information, advisory and consultancy services in relation to all of the aforesaid
- Class 044 — Medical, beauty and agricultural services: Medical services; medical diagnostic testing, analysis and diagnostic services for the treatment of patients in the field of antibodies; medical services for the treatment of diseases through the use of antibodies, ion channel modulating antibodies, and G-protein-coupled receptor modulating antibodies or antibodies derived from mini-protein toxins, or pharmaceuticals, drugs and pharmaceutical preparations derived from the aforesaid; information, advisory and consultancy services in relation to all of the aforesaid
Owner
Prosecution history
- 17 Feb 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 17 Feb 2026 — PUBLISHED FOR OPPOSITION
- 11 Feb 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 27 Jan 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 27 Jan 2026 — EXAMINER'S AMENDMENT ENTERED
- 27 Jan 2026 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 27 Jan 2026 — EXAMINERS AMENDMENT E-MAILED
- 27 Jan 2026 — EXAMINERS AMENDMENT -WRITTEN
- 22 Oct 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 21 Oct 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 21 Oct 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 21 Jun 2025 — REFUSAL PROCESSED BY IB
- 05 Jun 2025 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
- 05 Jun 2025 — REFUSAL PROCESSED BY MPU
- 02 Apr 2025 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW